Johnson & Johnson 株価情報 (NYSE: JNJ)

Johnson & Johnson (NYSE:JNJ) 株価情報

Johnson & Johnson

Johnson & Johnson is the world's largest and most diverse healthcare firm. It has two divisions: pharmaceutical and medical devices. These now represent all of the company's sales following the divestment of the consumer business, Kenvue, in 2023. The drug division focuses on the following therapeutic areas: immunology, oncology, neurology, pulmonary, cardiology, and metabolic diseases. Geographically, just over half of total revenue is generated in the United States.

Guggenheim analyst Vamil Divan reiterates Johnson &amp; Johnson (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>) from Neutral to Neutral.

News

Reiteration

Analyst Ratings

Guggenheim Reiterates Neutral on Johnson & Johnsonto Neutral

This whale alert can help traders discover the next big trading opportunities.
Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner.
Traders will search for circumstances when the market estimation of an option diverges heavily from its normal worth. High amounts of trading activity could push option prices to exaggerated or underestimated levels. 
Below are some instances of options activity happening in the Health Care sector: 
<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>VKTX</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>04/17/25</td>
<td>$35.00</td>
<td>$43.0K</td>
<td>680</td>
<td>1.7K</td>
</tr>
<tr>
<td>LLY</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>03/14/25</td>
<td>$815.00</td>
<td>$26.5K</td>
<td>38</td>
<td>268</td>
</tr>
<tr>
<td>BMY</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>09/19/25</td>
<td>$62.50</td>
<td>$125.9K</td>
<td>90</td>
<td>253</td>
</tr>
<tr>
<td>SYK</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>03/21/25</td>
<td>$360.00</td>
<td>$119.2K</td>
<td>472</td>
<td>203</td>
</tr>
<tr>
<td>ABBV</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>04/11/25</td>
<td>$210.00</td>
<td>$95.5K</td>
<td>290</td>
<td>193</td>
</tr>
<tr>
<td>IQV</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>12/19/25</td>
<td>$180.00</td>
<td>$200.2K</td>
<td>31</td>
<td>111</td>
</tr>
<tr>
<td>UNH</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>09/19/25</td>
<td>$490.00</td>
<td>$99.7K</td>
<td>92</td>
<td>77</td>
</tr>
<tr>
<td>JNJ</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>06/20/25</td>
<td>$165.00</td>
<td>$26.6K</td>
<td>6.1K</td>
<td>56</td>
</tr>
<tr>
<td>CI</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>09/19/25</td>
<td>$330.00</td>
<td>$80.8K</td>
<td>14</td>
<td>29</td>
</tr>
<tr>
<td>TMO</td>
<td>PUT</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>06/18/26</td>
<td>$600.00</td>
<td>$101.9K</td>
<td>0</td>
<td>10</td>
</tr>
</tbody>
</table>

<h2>Explanation</h2>
These itemized elaborations have been created using the accompanying table. 
• For VKTX (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VKTX#NASDAQ">VKTX</a>), we notice a call option trade that happens to be bullish, expiring in 37 day(s) on April 17, 2025. This event was a transfer of 426 contract(s) at a $35.00 strike. The total cost received by the writing party (or parties) was $43.0K, with a price of $101.0 per contract. There were 680 open contracts at this strike prior to today, and today 1750 contract(s) were bought and sold. 
• For LLY (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>), we notice a call option trade that happens to be neutral, expiring in 3 day(s) on March 14, 2025. This event was a transfer of 20 contract(s) at a $815.00 strike. The total cost received by the writing party (or parties) was $26.5K, with a price of $1325.0 per contract. There were 38 open contracts at this strike prior to today, and today 268 contract(s) were bought and sold. 
• For BMY (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BMY#NYSE">BMY</a>), we notice a put option sweep that happens to be bearish, expiring in 192 day(s) on September 19, 2025. This event was a transfer of 221 contract(s) at a $62.50 strike. This particular put needed to be split into 13 different trades to become filled. The total cost received by the writing party (or parties) was $125.9K, with a price of $570.0 per contract. There were 90 open contracts at this strike prior to today, and today 253 contract(s) were bought and sold. 
• For SYK (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SYK#NYSE">SYK</a>), we notice a put option trade that happens to be bearish, expiring in 10 day(s) on March 21, 2025. This event was a transfer of 200 contract(s) at a $360.00 strike. The total cost received by the writing party (or parties) was $119.2K, with a price of $596.0 per contract. There were 472 open contracts at this strike prior to today, and today 203 contract(s) were bought and sold. 
• For ABBV (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABBV#NYSE">ABBV</a>), we notice a put option sweep that happens to be bullish, expiring in 31 day(s) on April 11, 2025. This event was a transfer of 193 contract(s) at a $210.00 strike. This particular put needed to be split into 16 different trades to become filled. The total cost received by the writing party (or parties) was $95.5K, with a price of $495.0 per contract. There were 290 open contracts at this strike prior to today, and today 193 contract(s) were bought and sold. 
• Regarding IQV (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IQV#NYSE">IQV</a>), we observe a put option sweep with bullish sentiment. It expires in 283 day(s) on December 19, 2025. Parties traded 110 contract(s) at a $180.00 strike. This particular put needed to be split into 24 different trades to become filled. The total cost received by the writing party (or parties) was $200.2K, with a price of $1820.0 per contract. There were 31 open contracts at this strike prior to today, and today 111 contract(s) were bought and sold. 
• For UNH (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNH#NYSE">UNH</a>), we notice a put option trade that happens to be bullish, expiring in 192 day(s) on September 19, 2025. This event was a transfer of 23 contract(s) at a $490.00 strike. The total cost received by the writing party (or parties) was $99.7K, with a price of $4335.0 per contract. There were 92 open contracts at this strike prior to today, and today 77 contract(s) were bought and sold. 
• Regarding JNJ (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>), we observe a call option trade with bullish sentiment. It expires in 101 day(s) on June 20, 2025. Parties traded 35 contract(s) at a $165.00 strike. The total cost received by the writing party (or parties) was $26.6K, with a price of $760.0 per contract. There were 6139 open contracts at this strike prior to today, and today 56 contract(s) were bought and sold. 
• For CI (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CI#NYSE">CI</a>), we notice a put option trade that happens to be bullish, expiring in 192 day(s) on September 19, 2025. This event was a transfer of 26 contract(s) at a $330.00 strike. The total cost received by the writing party (or parties) was $80.8K, with a price of $3110.0 per contract. There were 14 open contracts at this strike prior to today, and today 29 contract(s) were bought and sold. 
• Regarding TMO (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TMO#NYSE">TMO</a>), we observe a put option trade with neutral sentiment. It expires in 464 day(s) on June 18, 2026. Parties traded 10 contract(s) at a $600.00 strike. The total cost received by the writing party (or parties) was $101.9K, with a price of $10193.0 per contract. There were 0 open contracts at this strike prior to today, and today 10 contract(s) were bought and sold. 
Options Alert Terminology 
 - Call Contracts: The right to buy shares as indicated in the contract. 
 - Put Contracts: The right to sell shares as indicated in the contract. 
 - Expiration Date: When the contract expires. One must act on the contract by this date if one wants to use it. 
 - Premium/Option Price: The price of the contract. 
For more information, visit our <a href="https://pro.benzinga.com/blog/how-to-understand-option-alerts/">Guide to Understanding Options Alerts</a> or read <a href="https://www.benzinga.com/markets/options">more about unusual options activity</a>. 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Options

ABBV

VKTX

10 Health Care Stocks Whale Activity In Today's Session

Companies with a long history of paying dividends and consistently hiking them remain appealing to income-focused investors. Exxon Mobil, Johnson &amp; Johnson, and Cogent Communications have rewarded shareholders for years and recently announced dividend increases. These companies currently offer dividend yields of up to 5%.
Exxon Mobil&nbsp;
Exxon Mobil Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XOM#NYSE">XOM</a>) engages in the exploration and production of crude oil and natural gas in the U.S. and internationally.
Exxon Mobil has raised its dividends every year for the last 42 years. According to its most recent dividend hike announcement on Nov. 1, the company increased the quarterly payout by 4% to $0.99 per share, which is equal to an annual figure of $3.96 per share. The current dividend yield is 3.76%.
Don't Miss:
<ul>
<li>It&#8217;s no wonder Jeff Bezos holds over $250 million in art — <a href="https://www.benzinga.com/money/masterworks">this alternative asset has outpaced the S&amp;P 500 since 1995, delivering an average annual return of 11.4%. Here&#8217;s how everyday investors are getting started.</a></li>
<li>Dogecoin millionaires are increasing –<a href="https://www.benzinga.com/money/dogecoin-millionaires"> investors with $1M+ in DOGE revealed!</a></li>
</ul>
Exxon Mobil&#8217;s annual revenue as of Dec. 31 stood at $339.25 billion. In its Q4 2024 earnings release on Jan. 31, the company posted quarterly revenues of $83.43 billion, missing the consensus estimate of $87.20 billion, while EPS of $1.67 came in above the consensus of $1.55.&nbsp;
If you invested $10,000 in Exxon Mobil stock 10 years ago, how much would you have now? Check out this <a href="https://www.benzinga.com/markets/25/01/43308384/if-you-invested-10-000-in-exxon-mobil-stock-10-years-ago-how-much-would-you-have-now">article by Benzinga</a> to learn more.
Johnson &amp; Johnson
Johnson &amp; Johnson (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>) engages in the research and development, manufacture, and sale of various products in the healthcare field worldwide.
Johnson &amp; Johnson has increased its dividends consecutively for the last 62 years. In its most recent dividend hike announcement on April 16, the company's board raised the quarterly payout by 4.2% to $1.24 per share, equal to an annual figure of $4.96 per share. Currently, the dividend yield on the stock is 3.00%.
Trending: <a href="https://www.benzinga.com/money/gbr-savings-by-age">If You're Age 35, 50, or 60: Here&#8217;s How Much You Should Have Saved Vs. Invested By Now</a>
Johnson &amp; Johnson&#8217;s annual revenue as of Dec. 31 stood at $88.82 billion. As per the company's Q4 2024 earnings report on Jan. 22, it posted revenues of $22.52 billion and EPS of $2.04. Both figures came in above the consensus estimates.
Check out this <a href="https://www.benzinga.com/insights/analyst-ratings/25/03/44151435/what-14-analyst-ratings-have-to-say-about-johnson-johnson">article by Benzinga</a> for 14 analysts' insights on Johnson &amp; Johnson.
Cogent Communications
Cogent Communications Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CCOI#NASDAQ">CCOI</a>) provides high-speed Internet access, private network, and data center colocation space services in North America, South America, Europe, Oceania, and Africa.
Cogent Communications has increased its dividend consecutively for the last 13 years. As per the company's most recent dividend announcement on Feb. 27, its board of directors raised the quarterly payout by $0.01 to $1.005 per share, which is equal to an annual figure of $4.02 per share. The dividend yield currently stands at 5.72%.
See Also: How do billionaires pay less in income tax than you?<a href="https://www.benzinga.com/money/tax-deferring-adv"> Tax deferring is their number one strategy</a>.
The company's annual revenue as of Dec. 31 stood at $1.04 billion. In its most recent earnings report on Feb. 27, it posted Q4 2024 revenues of $252.29 million, missing expectations, while the per-share loss of $0.91 came in better than feared.&nbsp;
Exxon Mobil, Johnson &amp; Johnson, and Cogent Communications are good choices for investors seeking reliable passive income. Their dividend yields of up to 5% and long history of consistent hikes make them attractive to income-focused investors.
Read Next:
<ul>
<li>BlackRock is calling 2025 the year of alternative assets. <a href="https://www.benzinga.com/money/masterworks">One firm from NYC has quietly built a group of 60,000+ investors who have all joined in on an alt asset class previously exclusive to billionaires like Bezos and Gates.</a></li>
<li><a href="https://www.benzinga.com/money/mark-cubans-advice-for-lotto-winners">Many are surprised by Mark Cuban's advice for lotto winners: Cash or annuity?</a></li>
</ul>

Personal Finance

CCOI

How Exxon Mobil, Johnson & Johnson, And Cogent Communications Can Put Cash In Your Pocket

Deep-pocketed investors have adopted a bullish approach towards Johnson &amp; Johnson (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>), and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this significant move today. The identity of these investors remains unknown, but such a substantial move in JNJ usually suggests something big is about to happen.
We gleaned this information from our observations today when Benzinga's options scanner highlighted 10 extraordinary options activities for Johnson &amp; Johnson. This level of activity is out of the ordinary.
The general mood among these heavyweight investors is divided, with 50% leaning bullish and 50% bearish. Among these notable options, 2 are puts, totaling $55,626, and 8 are calls, amounting to $1,285,602.
<h3>What's The Price Target?</h3>
Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $130.0 to $175.0 for Johnson &amp; Johnson over the recent three months. 
<h3>Volume &amp; Open Interest Development</h3>
Assessing the volume and open interest is a strategic step in options trading. These metrics shed light on the liquidity and investor interest in Johnson &amp; Johnson's options at specified strike prices. The forthcoming data visualizes the fluctuation in volume and open interest for both calls and puts, linked to Johnson &amp; Johnson's substantial trades, within a strike price spectrum from $130.0 to $175.0 over the preceding 30 days.
<h3>Johnson &amp; Johnson Call and Put Volume: 30-Day Overview</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1741622495_0.png" alt="Options Call Chart" />
<h3>Noteworthy Options Activity:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>JNJ</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>03/21/25</td>
<td>$2.07</td>
<td>$1.77</td>
<td>$1.97</td>
<td>$170.00</td>
<td>$689.5K</td>
<td>10.1K</td>
<td>3.6K</td>
</tr>
<tr>
<td>JNJ</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/15/27</td>
<td>$38.75</td>
<td>$37.4</td>
<td>$37.4</td>
<td>$140.00</td>
<td>$340.3K</td>
<td>207</td>
<td>91</td>
</tr>
<tr>
<td>JNJ</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/16/26</td>
<td>$10.0</td>
<td>$9.25</td>
<td>$10.0</td>
<td>$175.00</td>
<td>$75.0K</td>
<td>1.7K</td>
<td>98</td>
</tr>
<tr>
<td>JNJ</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/16/26</td>
<td>$15.6</td>
<td>$15.0</td>
<td>$15.0</td>
<td>$165.00</td>
<td>$49.5K</td>
<td>2.1K</td>
<td>0</td>
</tr>
<tr>
<td>JNJ</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>06/20/25</td>
<td>$40.95</td>
<td>$39.9</td>
<td>$39.85</td>
<td>$130.00</td>
<td>$39.8K</td>
<td>371</td>
<td>10</td>
</tr>
</tbody>
</table>

<h3>About Johnson &amp; Johnson</h3>
Johnson &amp; Johnson is the world's largest and most diverse healthcare firm. It has two divisions: pharmaceutical and medical devices. These now represent all of the company's sales following the divestment of the consumer business, Kenvue, in 2023. The drug division focuses on the following therapeutic areas: immunology, oncology, neurology, pulmonary, cardiology, and metabolic diseases. Geographically, just over half of total revenue is generated in the United States.
After a thorough review of the options trading surrounding Johnson &amp; Johnson, we move to examine the company in more detail. This includes an assessment of its current market status and performance.
<h3>Current Position of Johnson &amp; Johnson</h3>
<ul>
<li>Currently trading with a volume of 5,546,324, the JNJ's price is up by 1.16%, now at $168.63. </li>
<li>RSI readings suggest the stock is currently may be overbought.</li>
<li>Anticipated earnings release is in 36 days.</li>
</ul>
<h3>Expert Opinions on Johnson &amp; Johnson</h3>
2 market experts have recently issued ratings for this stock, with a consensus target price of $176.0.
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;adType=benzinga-insights&amp;ad=options-activity&amp;campaign=wallstreetadvantage">Click here for access</a>. 
&#x2A; Maintaining their stance, an analyst from B of A Securities continues to hold a Neutral rating for Johnson &amp; Johnson, targeting a price of $171. 
&#x2A; An analyst from RBC Capital has revised its rating downward to Outperform, adjusting the price target to $181. 
Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.
If you want to stay updated on the latest options trades for Johnson &amp; Johnson, <a href="https://www.benzinga.com/pro/">Benzinga Pro</a> gives you real-time options trades alerts.

Markets

Johnson & Johnson Options Trading: A Deep Dive into Market Sentiment

GMAB

CORRECTION: Genmab shares are trading lower after Johnson & Johnson decided not to exercise its option to receive a worldwide license to develop, manufacture, and commercialize HexaBody-CD38. Genmab will not pursue further clinical development.

<ul>
<li>Johnson &amp; Johnson has decided that it will not exercise its option to receive a worldwide license to develop, manufacture and commercialize HexaBody-CD38</li>
<li>Genmab will not pursue further clinical development of HexaBody-CD38</li>
<li>Data validates clinical potential of the HexaBody platform</li>
<li>Genmab to host a conference call today at 5:00 PM CET / 4:00 PM GMT / 12:00 PM EDT</li>
</ul>
COPENHAGEN, Denmark; March 10, 2025 – <a href="https://www.globenewswire.com/Tracker?data=2jy2jmHgLka6YSWX2AWjGnlxlSmdCYL8XdVOJE-3BVZVFYHLPZGygTz_h51hGpxCsleRY51478TNlNtDnnAt5Q==">Genmab A/S</a> (NASDAQ:<a href="https://www.benzinga.com/stock/GMAB#NASDAQ">GMAB</a>) announced today that Johnson &amp; Johnson (J&amp;J) has decided that it will not exercise its option to receive a worldwide license to develop, manufacture and commercialize HexaBody-CD38 (GEN3014). While the initial HexaBody-CD38 clinical data is promising and showed robust clinical efficacy, following a thorough evaluation of the data, the market landscape, and Genmab's rigorous portfolio prioritization, Genmab will not pursue further clinical development&nbsp;of HexaBody-CD38.

Biotech

Contracts

General

Genmab Announces Johnson & Johnson Has Decided That It Will Not Exercise Its Option To Receive A Worldwide License To Develop, Manufacture And Commercialize HexaBody-CD38; Genmab Will Not Pursue Further Clinical Development

On Monday, Protagonist Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PTGX#NASDAQ">PTGX</a>) announced topline results from ANTHEM-UC Phase 2b study of icotrokinra (JNJ-2113) in adults with moderately to severely active <a target="_blank" href="https://www.benzinga.com/general/biotech" rel="noreferrer noopener">ulcerative colitis (UC)</a>.
The study conducted by Protagonist&#8217;s collaboration partner, Johnson &amp; Johnson, met its primary endpoint of clinical response&nbsp;in all icotrokinra dose groups evaluated.
Additionally, the study demonstrated clinically meaningful differences versus placebo in key secondary endpoints of clinical remission, symptomatic remission and endoscopic <a target="_blank" href="https://www.benzinga.com/pressreleases/25/03/ac44217207/protagonist-reports-positive-top-line-results-from-phase-2b-study-of-icotrokinra-showing-potentia" rel="noreferrer noopener">improvement at Week 12</a>.
<ul>
<li>All three doses of once daily icotrokinra met the primary endpoint of clinical response at Week 12.</li>
<li>At Week 12, patients treated with the highest dose of icotrokinra achieved a response rate of 63.5% versus 27.0% for placebo.</li>
<li>30.2% of patients treated with the highest dose of icotrokinra demonstrated clinical remission at Week 12, compared to 11.1% of patients who received placebo.</li>
<li>Clinical remission and response rates continued to improve through Week 28.</li>
</ul>
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/25/03/44084427/takeda-protagonist-therapeutics-partnered-investigational-drug-hits-primary-goal-in-late-stage-study-in-patients-with-type-of-blood-cancer" rel="noreferrer noopener">Takeda-Protagonist Therapeutics Partnered Investigational Drug Hits Primary Goal In Late-Stage Study In Patients With Type Of Blood Cancer</a>
On Saturday, Johnson &amp; Johnson (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>) released new icotrokinra data from its comprehensive Phase 3 program in adults and adolescents 12 years and older with moderate-to-severe <a target="_blank" href="https://www.benzinga.com/pressreleases/25/03/ac44209279/icotrokinra-clinical-study-results-demonstrate-its-potential-to-shift-treatment-paradigm-and-set-" rel="noreferrer noopener">plaque psoriasis&nbsp;(PsO)</a>.
Data from the Phase 3 ICONIC-LEADa&nbsp;study, presented at the 2025 American Academy of Dermatology Annual Meeting, show once daily icotrokinra demonstrated significant skin clearance and a favorable safety profile.
In the ICONIC-LEAD study, nearly two-thirds (65%) of patients treated with once daily icotrokinra achieved an Investigator&#8217;s Global Assessment (IGA)b&nbsp;score of 0/1 (clear or almost clear skin) and 50% achieved a Psoriasis Area and Severity Index (PASI)c&nbsp;90 response, compared to 8% and 4% receiving placebo, respectively (P&lt;0.001 for both endpoints) at Week 16.
Continued skin clearance improvement was reported at Week 24. Up to 74% of patients treated with icotrokinra achieved IGA 0/1 and 65% achieved PASI 90.
At Week 24, nearly half of the patients treated with icotrokinra achieved completely clear skin – 46% reached IGA 0, and 40% reached PASI 100.
Similar proportions of patients experienced adverse events (AEs) between icotrokinra (49%) and placebo groups (49%), with no new safety signals identified.
Additionally, topline results show that the Phase 3 ICONIC-ADVANCE 1&amp;2e&nbsp;studies met their co-primary endpoints of IGA 0/1 and PASI 90 versus placebo at Week 16.
Icotrokinra also met all key secondary endpoints at Weeks 16 and 24 that measured superiority to Bristol-Myers Squibb&nbsp;&amp; Co&#8217;s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BMY#NYSE">BMY</a>) Sotyktu deucravacitinib in patients with moderate-to-severe plaque PsO.
Johnson &amp; Johnson is initiating the Phase 3 ICONIC-ASCENDg&nbsp;study, a head-to-head study of an oral pill, icotrokinra, compared to an injectable biologic, Stelars (ustekinumab).
Price Action: PTGX stock is up 35.9% at $52.42. JNJ stock is up 0.54% at $167.59 during the premarket session at the last check Monday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/03/44218003/franco-nevada-reports-stellar-q4-amid-record-gold-prices-eyes-25-revenue-growth-in-2025" target="_blank" rel="noreferrer noopener">Franco-Nevada Reports Solid Q4 Earnings Amid Record Gold Prices, Eyes 25% Revenue Growth In 2025</a></li>
</ul>

Large Cap

Health Care

Movers

Trading Ideas

PTGX

Why Is Protagonist Therapeutics Stock Trading Higher On Monday?

Phase 3 MARIPOSA study showed&nbsp;LAZCLUZE&#xAE; plus RYBREVANT&#xAE; significantly improved progression-free survival, reducing the risk of disease progression or death by 30 per cent versus osimertinib alone.1
TORONTO, March 10, 2025 /CNW/ - Johnson &amp; Johnson (NYSE:&nbsp;JNJ) announced today that Health Canada has issued a Notice of Compliance (NOC) for LAZCLUZE&#xAE; (lazertinib) in combination with RYBREVANT&#xAE; (amivantamab) for the first-line treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 L858R substitution mutations.1 Janssen Inc., a Johnson &amp; Johnson company, is the market authorization holder for LAZCLUZE &#xAE; and RYBREVANT&#xAE; in Canada.
With this authorization, LAZCLUZE&#xAE; plus RYBREVANT&#xAE; becomes the first and only chemotherapy-free combination regimen showing clinically meaningful and statistically significant improvement in progression-free survival versus osimertinib for these patients.1 RYBREVANT&#xAE; is a fully human bispecific antibody targeting EGFR and MET with immune cell-directing activity, and LAZCLUZE&#xAE; is a highly potent, brain penetrant,2 third-generation&nbsp;EGFR tyrosine kinase inhibitor (TKI).3,1

Global

Johnson & Johnson Announces Health Canada Authorizes LAZCLUZE In Combination With RYBREVANT As A First-Line Chemotherapy-Free Treatment For Patients With EGFR-Mutated Advanced Lung Cancer

Topline results also show investigational&nbsp;targeted oral peptide&nbsp;icotrokinra&nbsp;achieved clinical remission rates up to 30.2% at Week 12 and a favorable safety profile in Phase 2b ANTHEM-UC study
Clinical response and remission rates continued to improve through Week 28, building on strong data recently reported for the plaque psoriasis Phase 3 program
Icotrokinra demonstrates potential to offer therapeutic benefit and tolerability with a once daily oral treatment
SPRING HOUSE, Pa., March 10, 2025 /PRNewswire/ -- Johnson &amp; Johnson (NYSE:&nbsp;JNJ)&nbsp;today announced positive topline results from ANTHEM-UC, a Phase 2b study of icotrokinra (JNJ-2113), the first investigational targeted oral peptide that selectively blocks the IL-23 receptor, in adults with moderately to severely active ulcerative colitis (UC). The study met its primary endpoint of clinical responsea in all icotrokinra dose groups evaluated and demonstrated clinically meaningful differences versus placebo in key secondary endpoints of clinical remissionb, symptomatic remission and endoscopic improvement at Week 12.&nbsp;
In the ANTHEM-UC study (n=252), three doses of once daily icotrokinra were tested with all meeting the primary endpoint of clinical response at Week 12. A response rate of 63.5% for patients treated with the highest dose of icotrokinra was achieved at Week 12 versus 27% for placebo (p&lt;0.001). Further, 30.2% of patients treated with the highest dose of icotrokinra demonstrated clinical remission at Week 12 versus 11.1% of patients who received placebo (p&lt;0.001). Remission and response rates continued to improve through Week 28.1
Icotrokinra was well tolerated with proportions of participants reporting one or more adverse events (AEs) being similar between the icotrokinra dose groups and the placebo group.1

Johnson & Johnson Announces Icotrokinra Meets Primary Endpoint Of Clinical Response In Ulcerative Colitis Study And Shows Potential To Transform The Treatment Paradigm For Patients

During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a<a href="https://www.benzinga.com/yield-investments"> high dividend payout</a>.
Benzinga readers can review the latest analyst takes on their favorite stocks by visiting <a href="https://www.benzinga.com/analyst-stock-ratings">Analyst Stock Ratings</a> page. Traders can sort through Benzinga's extensive database of analyst ratings, including <a href="https://www.benzinga.com/analyst-ratings/analyst-color/22/09/28888638/exclusive-study-finds-benzinga-analyst-ratings-data-yields-market-beating-strategie">by analyst accuracy</a>.
Below are the ratings of the most accurate analysts for three high-yielding stocks in the health care sector.
<h3 class="wp-block-heading">CVS Health Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVS#NYSE">CVS</a>)</h3>
<ul>
<li>Dividend Yield: 4.01%</li>
<li>Truist Securities analyst David Macdonald maintained a Buy rating and raised the price target from $60 to $76 on Feb. 13, 2025. This analyst has an accuracy rate of 65%.</li>
<li>Leerink Partners analyst Michael Cherny upgraded the stock from Market Perform to Outperform and boosted the price target from $55 to $75 on Feb. 13, 2025. This analyst has an accuracy rate of 61%.</li>
<li>Recent News: On March 4, Wellvana and CVS Health disclosed that Wellvana has acquired the Medicare Shared Savings Program business of CVS Accountable Care&#x2122;, part of CVS Health, in an all-stock transaction.</li>
<li>Benzinga Pro&#8217;s real-time newsfeed alerted to latest <a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent031025&amp;t=be2bearmibe3na1">CVS news</a>. </li>
</ul>
<figure class="wp-block-image is-resized"><a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent031025&amp;t=be2bearmibe3na1"><img decoding="async" src="blob:https://editorial.benzinga.com/59c9cf91-f220-445e-9cc8-fb8e60e12227" alt="" style="width:620px;height:auto" /></a></figure>
<h3 class="wp-block-heading">Bristol-Myers Squibb Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BMY#NYSE">BMY</a>)</h3>
<ul>
<li>Dividend Yield: 4.06%</li>
<li>Wells Fargo analyst Mohit Bansal maintained an Equal-Weight rating and raised the price target from $60 to $62 on Feb. 7, 2025. This analyst has an accuracy rate of 74%.</li>
<li>Citigroup analyst Andrew Baum maintained a Neutral rating and boosted the price target from $60 to $65 on Jan. 28, 2025. This analyst has an accuracy rate of 72%.</li>
<li>Recent News: On March 7, the European Commission (EC) approved Bristol Myers Squibb's Opdivo (nivolumab) plus Yervoy (ipilimumab) for the first-line treatment of adult patients with unresectable or advanced hepatocellular carcinoma (HCC), a type of liver cancer.</li>
<li>Benzinga Pro's real-time newsfeed alerted to latest <a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent031025&amp;t=be2bearmibe3na1">BMY news</a> </li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent031025&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="910" height="831" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/09221826/image-43.png" alt="" class="wp-image-815700" style="width:563px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/09221826/image-43.png 910w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/09221826/image-43-300x274.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/09221826/image-43-768x701.png 768w" sizes="(max-width: 910px) 100vw, 910px" /></a></figure>
<h3 class="wp-block-heading">Johnson &amp; Johnson (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>)</h3>
<ul>
<li>Dividend Yield: 2.98%</li>
<li>Guggenheim analyst Vamil Divan maintained a Neutral rating and raised the price target from $162 to $166 on Feb. 3, 2025. This analyst has an accuracy rate of 76%.</li>
<li>Barclays analyst Matt Miksic maintained an Equal-Weight rating and increased the price target from $159 to $166 on Jan. 28, 2025. This analyst has an accuracy rate of 69%.</li>
<li>Recent News: On March 7, Johnson &amp; Johnson decided to discontinue the Phase 3 VENTURA development program evaluating aticaprant, a kappa opioid receptor (KOR) antagonist, as an adjunctive treatment for major depressive disorder (aMDD).</li>
<li>Benzinga Pro&#8217;s real-time newsfeed alerted to <a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent031025&amp;t=be2bearmibe3na1">latest JNJ news</a> </li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent031025&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="905" height="827" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/09221911/image-44.png" alt="" class="wp-image-815702" style="width:570px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/09221911/image-44.png 905w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/09221911/image-44-300x274.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/09221911/image-44-768x702.png 768w" sizes="(max-width: 905px) 100vw, 905px" /></a></figure>
<figure class="wp-block-embed is-type-video is-provider-youtube wp-block-embed-youtube wp-embed-aspect-16-9 wp-has-aspect-ratio"> 
<div class="wp-block-embed__wrapper">
<iframe loading="lazy" title="How to Find Dividend Stocks: Scan, Analyze, and Capture with Benzinga Pro" width="500" height="281" src="https://www.youtube.com/embed/pVF0O2lsEH4?start=1&#038;feature=oembed" frameborder="0" allow="accelerometer; autoplay; clipboard-write; encrypted-media; gyroscope; picture-in-picture; web-share" referrerpolicy="strict-origin-when-cross-origin" allowfullscreen></iframe>
</div>
</figure>
Read More: 
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/long-ideas/25/03/44187903/top-2-consumer-stocks-that-could-blast-off-this-quarter">Top 2 Consumer Stocks That Could Blast Off This Quarter</a></li>
</ul>

Price Target

Pre-Market Outlook

Wall Street's Most Accurate Analysts Give Their Take On 3 Health Care Stocks Delivering High-Dividend Yields

<ul>
<li>Standout combination of complete skin clearance and favorable safety profile in a once daily pill could shift treatment paradigm</li>
<li>Nearly half of patients with moderate-to-severe plaque psoriasis (PsO) treated with investigational icotrokinra achieved completely clear skin (IGA 0) at Week 24 in Phase 3 ICONIC-LEAD</li>
<li>Topline results from Phase 3 ICONIC-ADVANCE 1&amp;2&nbsp;studies show icotrokinra achieved co-primary endpoints and showed superiority to deucravacitinib in moderate-to-severe plaque PsO</li>
<li>These results pave the way to initiate the first-ever head-to-head study seeking to demonstrate the superiority of a pill versus injectable biologic in moderate-to-severe plaque PsO</li>
</ul>

Reported Saturday, Johnson & Johnson's Icotrokinra Achieves Complete Skin Clearance In 46% Of Patients At Week 24, Showing Potential To Redefine Psoriasis Treatment

<img alt="ETF Exchange traded fund Investment finance concept. Abstract background." class="article-image-one" src="https://www.marketbeat.com/logos/articles/med_20250304100712_broaden-your-etf-exposure-with-these-3-overlooked.jpg" style="height:504px; width:1200px" />
Volatility is surging, with the <a href="https://www.marketbeat.com/financial-terms/learning-about-the-vix-volatilty-index/">VIX &quot;fear&quot; index</a> climbing to its highest level so far in 2025 as of March 3. Investors have been spooked by an inverted yield curve in Treasury rates and corresponding concerns about a potential recession, as well as uncertainty surrounding tariffs by the Trump administration, dropping consumer confidence levels, and more. In the midst of these challenges, exchange-traded funds (ETFs) can be a haven and a way to diversify a portfolio to protect against headwinds.
Investors looking to expand their ETF focus in the new year might consider any number of defensive plays that aim to minimize downside risk in a tumultuous market. More adventurous investors might also use this as an opportunity to invest in underappreciated ETFs&mdash;funds that have had a strong showing so far in 2025 but which have relatively modest assets under management of $25 billion or less. These are not the most obscure ETFs available&mdash;to be sure, there are plenty with asset bases just a fraction of that level&mdash;but they are also well behind many of the most popular ETF options investors tend to gravitate toward.
<h2>Strong 2025 Performance and Global Exposure With High Dividends</h2>
The <a href="https://www.marketbeat.com/stocks/BATS/EFV/">iShares MSCI EAFE Value ETF (BATS: </a><a class="ticker" href="https://www.benzinga.com/stock/efv#BATS">EFV</a>) may appeal to investors seeking increased exposure to equities outside of the North American space. Focusing on Europe, Australia, Asia, and the Far East (EAFE), EFV prioritizes companies with value characteristics such as low pricing multiples.
[content-module:CompanyOverview|BATS:EFV]
Value stocks have seen success as a group early in 2025, and EFV bets that these trends will continue, at least outside of the United States and Canada.
A key draw of EFV is its wide reach. The fund&#39;s nearly 450 holdings are tilted toward financials (about 34% of the portfolio as of February 28), but all sectors are represented. Similarly, though Japan, the United Kingdom, and France are the countries best represented in EFV&#39;s basket of stocks, companies from more than a dozen nations are included.
Many of the names in EFV&#39;s portfolio also maintain high dividend yields, and the fund itself has an annual dividend yield of 4.29%, giving investors a key added bonus of regular passive income. As of March 3, EFV has surged by about 11% so far in 2025, while the S&amp;P 500 is down 0.3% over the same period.
<h2>Low-Cost Global Exposure, Solid 2025 Returns</h2>
Investors seeking an ETF similar to EFV above but with a broader basket and a lower expense ratio might consider the <a href="https://www.marketbeat.com/stocks/NYSEARCA/SPDW/">SPDR S&amp;P World ex-US ETF (NYSEARCA: SPDW)</a>.
[content-module:CompanyOverview|NYSEARCA:SPDW]
While EFV&#39;s annual fee will cost investors 0.33%, SPDW&#39;s is a mere 0.03%, making it one of the least expensive ETFs available.
Further, SPDW&#39;s investment mandate is exceptionally wide&mdash;the fund holds a huge portfolio of large-cap developed international equities outside the United States. With extensive exposure to nearly 5,000 stocks, SPDW remains broadly diversified without a distinct geographic or sector focus.
However, it makes an excellent play when global markets are thriving, and the U.S. may be struggling&mdash;or for investors simply looking to rebalance their portfolio away from a common U.S. tilt. SPDW&#39;s strategy is paying off so far this year, with returns of nearly 8% so far as of March 3.
<h2>Modest Assets Don&#39;t Interfere With Stable Holdings, High Dividend Yield</h2>
Unlike the funds above, the <a href="https://www.marketbeat.com/stocks/NYSEARCA/HDV/">iShares Core High Dividend ETF (NYSEARCA: HDV)</a> does focus on U.S. equities&mdash;specifically, on <a href="https://www.marketbeat.com/compare-stocks/dividend-stocks/">dividend-paying</a> large-caps that show signs of being undervalued.
[content-module:CompanyOverview|NYSEARCA:HDV]
The 76 companies in HDV&#39;s portfolio include household names like&nbsp;<a href="https://www.marketbeat.com/stocks/NYSE/JNJ/">Johnson &amp; Johnson (NYSE: </a><a class="ticker" href="https://www.benzinga.com/stock/jnj#NYSE">JNJ</a>) and <a href="https://www.marketbeat.com/stocks/NYSE/PG/">Procter &amp; Gamble Co. (NYSE: </a><a class="ticker" href="https://www.benzinga.com/stock/pg#NYSE">PG</a>).
Companies like these are incredibly well established, likely to continue to see strong business even in the face of challenging external economic conditions, and appealing to investors for their history of dividend payments.
HDV sports a fairly high annual dividend yield of 3.44%. The stable status of the individual stocks making up HDV&#39;s portfolio means the fund has also fared well so far in 2025 despite uncertainty in the market. HDV is up more than 7% year-to-date as of March 3. What&#39;s more, its low expense ratio of 0.08% makes it competitive with many other dividend funds. It&#39;s surprising, then, that HDV has an AUM of just $11 billion, making it the smallest fund on this list based on asset base.
<h2><a href="https://www.marketbeat.com/newsletter/PDFoffer.aspx?offer=top5&amp;RegistrationCode=SyndicatedArticleLink" style="text-decoration:none;color:var(--dark-blue); font-weight:500;">Where Should You Invest $1,000 Right Now?</a></h2>
Before you make your next trade, you&#39;ll want to hear this.
MarketBeat keeps track of Wall Street&#39;s top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis.
Our team has identified the <a href="https://www.marketbeat.com/newsletter/PDFoffer.aspx?offer=top5&amp;RegistrationCode=SyndicatedArticleLink">five stocks</a> that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and none of the big name stocks were on the list.
They believe these five stocks are the five best companies for investors to buy now...
<a class="btn btn-featured" href="https://www.marketbeat.com/newsletter/PDFoffer.aspx?offer=top5&amp;RegistrationCode=SyndicatedArticleLink" style="text-decoration:none">See The Five Stocks Here </a>
The article &quot;<a href="https://www.marketbeat.com/stock-ideas/broaden-your-etf-exposure-with-these-3-overlooked-funds/">Broaden Your ETF Exposure With These 3 Overlooked Funds</a>&quot; first appeared on MarketBeat.

ETFs

Broaden Your ETF Exposure With These 3 Overlooked Funds

<ul>
<li>CDC study follows measles outbreak amid declining vaccination rates</li>
<li>Kennedy's mixed messages on vaccines raise concerns</li>
<li>Autism rise attributed to broader screening, not vaccines</li>
</ul>
March 7 - The U.S. Centers for Disease Control and Prevention is planning a large study into potential connections between vaccines and autism, two sources familiar with the matter told Reuters, despite extensive scientific research that has disproven or failed to find evidence of such links.
It is unclear whether U.S. Health Secretary Robert F. Kennedy Jr, who has long promoted <a href="reuters://REALTIME/verb=NewsStory/ric=nL2N3PH1HA">anti-vaccine views</a>, is involved in the planned CDC study or how it would be carried out. The CDC and the Department of Health and Human Services were not immediately available for comment.
The CDC's move comes amid one of the largest <a href="reuters://REALTIME/verb=NewsStory/ric=nL3N3PN1WV">measles outbreaks</a> the U.S. has seen in the past decade, with more than 150 cases and two deaths in Texas and New Mexico. The outbreak has been fueled by declining vaccination rates in parts of the United States where parents have been falsely persuaded that such shots do more harm than good.
Kennedy, whose role includes authority over the CDC, has long sowed doubt over the safety of the combined vaccine for measles, mumps and rubella (MMR). In a cabinet meeting last week, Kennedy initially downplayed news that a school-aged child had died of measles in Texas, the first such death in a decade, calling such outbreaks ordinary and failing to mention the role of vaccination to prevent measles.
Over the weekend, Kennedy published an opinion piece on Fox News that promoted the role of vaccination, but also told parents vaccination was a personal choice and urged them to consult with their physician.
Kennedy did not immediately respond to a request for comment.
Autism diagnoses in the United States have increased significantly since 2000, intensifying public concern.
Many researchers attribute the <a href="reuters://REALTIME/verb=NewsStory/ric=nL1N3NJ17A">rise in diagnoses</a> to more widespread screening and the inclusion of a broader range of behaviors to describe the condition. But some public figures have popularized the idea that vaccines are to blame, an idea stemming from a since-debunked study from British researcher Andrew Wakefield in the late 1990s that connected a rise in autism diagnoses with widespread use of the MMR shot.
The causes of autism are unclear. No rigorous studies have found links between autism and vaccines or medications, or their components such as thimerosal or formaldehyde.
There is widespread speculation among scientists that its neurological characteristics may develop in utero, when the fetal brain is being wired. Studies have linked autism to maternal factors in pregnancy, and some research suggests a link to birth complications and timing.
President Donald Trump, in an address to Congress this week, cited the rise in autism among children. "So, we're going to find out what it is, and there's nobody better than Bobby and all of the people that are working with you," Trump said, referring to Kennedy.
Kennedy's anti-vaccine views have drawn concern among some Republicans. During Kennedy's confirmation hearing Senator Bill Cassidy, a Louisiana Republican and physician, suggested that the nominee disavow any links between vaccines and autism.
Kennedy denied that he was anti-vaccine, but did not acknowledge that such a link had been debunked.
This week Cassidy questioned Trump's nominee to lead the National Institutes of Health, Dr. Jay Bhattacharya, over his stance on investigating a potential link between autism and childhood vaccinations.
"I don't generally believe there is a link, based on my reading of the literature," Bhattacharya said. "But we do have a sharp rise in autism rates, and I don't think any scientist really knows the cause of it. I would support a broad scientific agenda based on data to get an answer to that."

BNTX

MRNA

'U.S. CDC Plans Large Study Into Potential Connections Between Vaccines And Autism, Sources Say' - Reuters News

On Friday, Johnson &amp; Johnson (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>) decided to discontinue the Phase 3 VENTURA development program evaluating aticaprant, a kappa opioid receptor (KOR) antagonist, as an adjunctive treatment for major <a target="_blank" href="https://www.benzinga.com/news/large-cap" rel="noreferrer noopener">depressive disorder (aMDD)</a>.
The move follows insufficient efficacy in the target patient population. The data confirmed aticaprant is safe and well-tolerated, and no new safety signals were identified.
The company <a target="_blank" href="https://www.jnj.com/media-center/press-releases/johnson-johnson-statement-on-ventura-program" rel="noreferrer noopener">will</a> explore future development opportunities for aticaprant. Full analyses from the VENTURA development program are underway and will be shared at a future medical meeting.
In January, &nbsp;Neumora Therapeutics, Inc.&#8217;s&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NMRA#NASDAQ">NMRA</a>) released data from the Phase 3 KOASTAL-1 Study of navacaprant for <a target="_blank" href="https://www.benzinga.com/general/biotech/25/01/42763345/neumora-therapeutics-depression-drug-fails-in-first-of-three-pivotal-phase-3-trials" rel="noreferrer noopener">major depressive disorder</a>.
The study did not demonstrate a statistically significant improvement on the primary endpoint of change from baseline in the Montgomery-Åsberg Depression Rating Scale (MADRS) total score at Week 6 or the key secondary endpoint of a change from baseline in the Snaith-Hamilton Pleasure Scale (SHAPS) scale.
Navacaprant, like aticaprant, is a kappa opioid receptor antagonist. Johnson &amp; Johnson says it continues to build on its leadership in Neuroscience.
In January, the healthcare giant agreed to acquire&nbsp;Intra-Cellular Therapies Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ITCI#NASDAQ">ITCI</a>) for $132.00 per share in cash for a total equity value of&nbsp;<a target="_blank" href="https://www.benzinga.com/general/biotech/25/01/42948170/like-bristol-myers-squibb-and-abbvie-johnson-johnson-seeks-to-bolster-neuropsychiatric-portfolio-with-15-billion-deal" rel="noreferrer noopener">approximately $14.6 billion</a>.
Johnson &amp; Johnson&#8217;s other depression drug Spravato (esketamine), in January, received FDA approval as the only monotherapy for adults living with major depressive disorder who have had an inadequate response to at least <a target="_blank" href="https://www.benzinga.com/general/biotech/25/01/43105398/fda-approves-johnson-johnsons-treatment-as-first-monotherapy-for-treatment-resistant-depression" rel="noreferrer noopener">two oral antidepressants</a>.
In 2024, Spravato generated global sales of <a target="_blank" href="https://www.benzinga.com/25/01/43125966/johnson-johnson-reports-q4-earnings-above-wall-street-estimates-driven-by-strong-cancer-drugs-revenue" rel="noreferrer noopener">around $1.01 billion</a>. In May 2024, Johnson &amp; Johnson&nbsp;topline results from Phase 3 MDD3001 clinical trial evaluating the efficacy and safety of seltorexant as an adjunctive treatment to baseline antidepressants in adult and elderly patients with major depressive disorder <a target="_blank" href="https://www.benzinga.com/general/biotech/24/05/39069469/johnson-johnsons-drug-seltorexant-aces-late-stage-depression-trial" rel="noreferrer noopener">with insomnia symptoms</a>.
The study achieved all primary and secondary endpoints, with seltorexant demonstrating both a statistically significant and clinically meaningful improvement in depressive symptoms and improved sleep disturbance outcomes in patients who had a prior inadequate response to SSRI/SNRI antidepressants alone.
Price Action: JNJ stock is down 0.20% at $165.50 during the premarket session at the last check Friday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/03/44175948/alzheimers-drugs-from-eli-lilly-and-biogen-still-deemed-too-costly-for-nhs-funding" target="_blank" rel="noreferrer noopener">Alzheimer&#8217;s Drugs From Eli Lilly And Biogen Still Deemed Too Costly For NHS Funding</a></li>
</ul>
Photo via Shutterstock

ITCI

NMRA

Johnson & Johnson Stops Late-Stage Depression Study Over 'Insufficient Efficacy'

HC Wainwright has initiated coverage on ImmunityBio, Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IBRX#NASDAQ">IBRX</a>). The company's lead asset is Anktiva (nogapendekin alfa inbakicept-pmln) solution for intravesical use, approved by the Food and Drug Administration indicated with Bacillus Calmette-Guérin (BCG) for adult patients with BCG-unresponsive bladder carcinoma in situ (CIS) with or <a href="https://www.benzinga.com/general/biotech">without papillary tumors</a>.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/25/01/43038889/immunitybio-stock-trading-higher-on-updates-from-bladder-cancer-trials-details" rel="noreferrer noopener">ImmunityBio Stock Trading Higher On Updates From Bladder Cancer Trials: Details</a>
HC Wainwright analyst Andres Y. Maldonado writes that Anktiva will follow a different market path than the two latest FDA-approved treatments for high-risk bladder cancer—Merck &amp; Co Inc's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MRK#NYSE">MRK</a>) Keytruda and Ferring Pharmaceutical's Adstiladrin—both of which have faced hurdles after launch.
Keytruda's adoption has been slow because urologists are hesitant to refer patients to oncologists and worry about its side effects. Adstiladrin, on the other hand, has struggled with supply issues, though Ferring says availability has recently improved.
HC Wainwright projects 2025 Anktiva revenue of $137.4 million, growing to $4.3 billion by 2034. The analyst has initiated with a Buy rating <a href="https://www.benzinga.com/quote/IBRX/analyst-ratings" target="_blank" rel="noreferrer noopener">and an $8 price target</a>.
In the fourth quarter, ImmunityBio reported <a href="https://www.benzinga.com/pressreleases/25/03/b44073991/immunitybio-reports-sales-momentum-unit-growth-since-permanent-j-code-issuance-j9028-in-january-20">product revenue of $7.21 million</a> and $14.2 million in the fiscal year 2024. The increase was driven by sales of ANKTIVA after FDA <a href="https://www.benzinga.com/general/biotech/24/04/38380405/fda-approves-immunitybios-bladder-cancer-drug-stock-rallies" target="_blank" rel="noreferrer noopener">approval in April 2024</a>.
Recently, the FDA granted Regenerative Medicine Advanced Therapy (RMAT) designation for Anktiva and CAR-NK (PD-L1 t-haNK) for the reversal of lymphopenia in patients receiving standard-of-care chemotherapy/radiotherapy and in multiply relapsed locally advanced or <a target="_blank" href="http://lymphopenia in patients receiving standard-of-care chemotherapy/radiotherapy and in multiply relapsed locally advanced or metastatic pancreatic cancer." rel="noreferrer noopener">metastatic pancreatic cancer</a>.
While many are watching the competition between CG Oncology Inc's (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CGON#NASDAQ">CGON</a>) cretostimogene and Johnson &amp; Johnson's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>) TAR-200 in the NMIBC market, Anktiva stands out with a first-mover advantage in a market potentially worth over $5 billion, the analyst says.
&#8220;Ultimately, we believe ANKTIVA's profile coupled with ease of administration will weigh more heavily in treatment decisions than comparisons of complete response (CR) rates at various time points to unapproved products,&#8221; the analyst writes.
Price Action: IBRX stock is down 2.47% at $2.98 at last check Thursday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/government/regulations/25/03/44169989/federal-judge-halts-national-institutes-of-healths-grant-policy-overhaul-citing-legal-violations" target="_blank" rel="noreferrer noopener">Federal Judge Halts National Institutes of Health&#8217;s Grant Policy Overhaul Citing Legal Violations</a></li>
</ul>
Photo: Shutterstock

Analyst Color

Initiation

CGON

IBRX

ImmunityBio Analyst Predicts Strong 2025 For New Bladder Cancer Drug

<a href="https://www.gov.uk/government/news/lazertinib-approved-for-use-in-combination-with-amivantamab-for-the-treatment-of-adults-with-non-small-cell-lung-cancer" title="https://www.gov.uk/government/news/lazertinib-approved-for-use-in-combination-with-amivantamab-for-the-treatment-of-adults-with-non-small-cell-lung-cancer">https://www.gov.uk/government/news/lazertinib-approved-for-use-in-combination-with-amivantamab-for-the-treatment-of-adults-with-non-small-cell-lung-cancer</a>

UK's MHRA: Lazertinib Approved For Use in Combination With Amivantamab For Treatment Of Adults With Non-small Cell Lung Cancer

14 analysts have shared their evaluations of Johnson &amp; Johnson (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>) during the recent three months, expressing a mix of bullish and bearish perspectives.
In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">1</td>
<td align="right">4</td>
<td align="right">9</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">3</td>
<td align="right">6</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $166.36, along with a high estimate of $181.00 and a low estimate of $152.00. A 2.41% drop is evident in the current average compared to the previous average price target of $170.46. 
<img src="https://www.benzinga.com/files/images/story/2025/1741208426_0.png" alt="price target chart" />
<h2>Diving into Analyst Ratings: An In-Depth Exploration</h2>
An in-depth analysis of recent analyst actions unveils how financial experts perceive Johnson &amp; Johnson. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tim Anderson</td>
<td>B of A Securities</td>
<td>Raises</td>
<td>Neutral</td>
<td>$171.00</td>
<td>$159.00</td>
</tr>
<tr>
<td>Shagun Singh</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$181.00</td>
<td>$181.00</td>
</tr>
<tr>
<td>Vamil Divan</td>
<td>Guggenheim</td>
<td>Raises</td>
<td>Neutral</td>
<td>$166.00</td>
<td>$162.00</td>
</tr>
<tr>
<td>Matt Miksic</td>
<td>Barclays</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$166.00</td>
<td>$159.00</td>
</tr>
<tr>
<td>Shagun Singh</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$181.00</td>
<td>$181.00</td>
</tr>
<tr>
<td>Terence Flynn</td>
<td>Morgan Stanley</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$163.00</td>
<td>$175.00</td>
</tr>
<tr>
<td>Rick Wise</td>
<td>Stifel</td>
<td>Lowers</td>
<td>Hold</td>
<td>$155.00</td>
<td>$170.00</td>
</tr>
<tr>
<td>David Risinger</td>
<td>Leerink Partners</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$169.00</td>
<td>$182.00</td>
</tr>
<tr>
<td>Larry Biegelsen</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$152.00</td>
<td>$166.00</td>
</tr>
<tr>
<td>Jayson Bedford</td>
<td>Raymond James</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$165.00</td>
<td>$170.00</td>
</tr>
<tr>
<td>Tim Anderson</td>
<td>B of A Securities</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$159.00</td>
<td>$160.00</td>
</tr>
<tr>
<td>Tim Anderson</td>
<td>B of A Securities</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$160.00</td>
<td>$166.00</td>
</tr>
<tr>
<td>Joanne Wuensch</td>
<td>Citigroup</td>
<td>Lowers</td>
<td>Buy</td>
<td>$175.00</td>
<td>$185.00</td>
</tr>
<tr>
<td>Tim Anderson</td>
<td>B of A Securities</td>
<td>Announces</td>
<td>Neutral</td>
<td>$166.00</td>
<td>-</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Johnson &amp; Johnson. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analysts unravel qualitative evaluations for stocks, ranging from 'Outperform' to 'Underperform'. These ratings offer insights into expectations for the relative performance of Johnson &amp; Johnson compared to the broader market.</li>
<li>Price Targets: Analysts provide insights into price targets, offering estimates for the future value of Johnson &amp; Johnson's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Considering these analyst evaluations in conjunction with other financial indicators can offer a comprehensive understanding of Johnson &amp; Johnson's market position. Stay informed and make well-informed decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/JNJ/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Johnson &amp; Johnson analyst ratings.</a>
<h2>Discovering Johnson &amp; Johnson: A Closer Look</h2>
Johnson &amp; Johnson is the world's largest and most diverse healthcare firm. It has two divisions: pharmaceutical and medical devices. These now represent all of the company's sales following the divestment of the consumer business, Kenvue, in 2023. The drug division focuses on the following therapeutic areas: immunology, oncology, neurology, pulmonary, cardiology, and metabolic diseases. Geographically, just over half of total revenue is generated in the United States.
<h3>Unraveling the Financial Story of Johnson &amp; Johnson</h3>
Market Capitalization: Surpassing industry standards, the company's market capitalization asserts its dominance in terms of size, suggesting a robust market position.
Positive Revenue Trend: Examining Johnson &amp; Johnson's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 5.26% as of 31 December, 2024, showcasing a substantial increase in top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: Johnson &amp; Johnson's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 15.24% net margin, the company effectively manages costs and achieves strong profitability.
Return on Equity (ROE): The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of 4.84%, the company showcases effective utilization of equity capital.
Return on Assets (ROA): The company's ROA is a standout performer, exceeding industry averages. With an impressive ROA of 1.91%, the company showcases effective utilization of assets.
Debt Management: With a below-average debt-to-equity ratio of 0.51, Johnson &amp; Johnson adopts a prudent financial strategy, indicating a balanced approach to debt management.
<h2>What Are Analyst Ratings?</h2>
Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.
Beyond their standard evaluations, some analysts contribute predictions for metrics like growth estimates, earnings, and revenue, furnishing investors with additional guidance. Users of analyst ratings should be mindful that this specialized advice is shaped by human perspectives and may be subject to variability.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

What 14 Analyst Ratings Have To Say About Johnson & Johnson

B of A Securities analyst Tim Anderson maintains Johnson &amp; Johnson (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>) with a Neutral and raises the price target from $159 to $171.

B of A Securities Maintains Neutral on Johnson & Johnson, Raises Price Target to $171

<a href="https://www.jnj.com/media-center/press-releases/shockwave-medical-launches-novel-forward-intravascular-lithotripsy-platform-in-u-s-to-transform-treatment-of-difficult-to-cross-calcified-lesions" title="https://www.jnj.com/media-center/press-releases/shockwave-medical-launches-novel-forward-intravascular-lithotripsy-platform-in-u-s-to-transform-treatment-of-difficult-to-cross-calcified-lesions">https://www.jnj.com/media-center/press-releases/shockwave-medical-launches-novel-forward-intravascular-lithotripsy-platform-in-u-s-to-transform-treatment-of-difficult-to-cross-calcified-lesions</a>

Johnson & Johnson MedTech Says 'Shockwave Medical Launches Novel Forward Intravascular Lithotripsy Platform In U.S. To Transform Treatment Of Difficult-To-Cross Calcified Lesions'

Press Releases

New nipocalimab data published in mAbs journal details differentiated molecular design, clinical profile and potential of nipocalimab to treat IgG-driven alloantibody and autoantibody diseases

GeminiBio Appoints Mike Stella to Board

TREMFYA® (guselkumab) subcutaneous (SC) induction data support potential to be the first and only in its class to offer the option of both intravenous and SC induction therapy in ulcerative colitis

INTRA-CELLULAR THERAPIES INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Intra-Cellular Therapies, Inc. - ITCI

Johnson & Johnson Announces Darren Snellgrove as Vice President, Investor Relations

Johnson & Johnson to Host Investor Conference Call on First-Quarter Results

Icotrokinra results show potential to set a new standard of treatment in plaque psoriasis

Icotrokinra meets primary endpoint of clinical response in ulcerative colitis study and shows potential to transform the treatment paradigm for patients

Health Canada authorizes LAZCLUZE® (lazertinib) in combination with RYBREVANT® (amivantamab) as a first-line chemotherapy-free treatment for patients with EGFR-mutated advanced lung cancer

Six Dean Omar Branham Shirley Partners Honored for Representation of Plaintiffs

AMGN

Amneal Pharmaceuticals, Inc. - Class A Common Stock

Amneal Pharmaceuticals

Axsome Therapeutics

AstraZeneca PLC - American Depositary Shares

AstraZeneca

Bristol-Myers Squibb Company Common Stock

Bristol-Myers Squibb

Corcept Therapeutics Incorporated - Common Stock

Corcept Therapeutics

Elanco Animal Health Incorporated Common Stock

Elanco Animal Health

GSK plc American Depositary Shares (Each representing two Ordinary Shares)

Haleon plc American Depositary Shares (Each representing two Ordinary Shares)

Haleon

Intra-Cellular Therapies Inc. - Common Stock

Intra-Cellular Therapies

Jazz Pharmaceuticals plc - Ordinary Shares

Jazz Pharmaceuticals

Eli Lilly

Merck & Co

Novo Nordisk

Novartis

Organon

Prestige Consumer Healthcare Inc. Common Stock

Prestige Consumer

Pfizer

Dr. Reddy's Laboratories Ltd Common Stock

Dr Reddy's Laboratories

Royalty Pharma plc - Class A Ordinary Shares

Royalty Pharma

Sanofi

Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)

Takeda Pharmaceutical Co

Teva Pharmaceutical Industries Limited American Depositary Shares

Teva Pharmaceutical Indus

Verona Pharma plc - American Depositary Shares

Verona Pharma

Viatris

Zoetis

B of A Securities

RBC Capital

Barclays

Morgan Stanley

Stifel

Screenshot 2024-09-30 at 9.13.36 PM

TNXP

VRTX

The Rush For Non-Addictive Painkillers To Counter The Opioid Crisis Puts Two Companies Closer To FDA Decisions

Screenshot 2024-04-30 at 5.36.02 PM

Cardio Diagnostics Holdings Inc. - Common stock

Comments

Johnson & Johnson

ニュース

パートナーシップ

ベンジンガ・グローバル